Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,739,645.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $498.91, for a total value of $4,739,645.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $161,867,857.13. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 2.1%

Shares of NASDAQ UTHR opened at $529.14 on Thursday. The firm’s 50-day simple moving average is $534.23 and its 200 day simple moving average is $537.17. The stock has a market cap of $22.69 billion, a P/E ratio of 18.93, a P/E/G ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $6.41 EPS. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter valued at $26,000. Toth Financial Advisory Corp lifted its holdings in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the period. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics in the second quarter worth $30,000. Finally, WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.